Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma

• Published in: Cancer cell Vol. 32; no. 3; pp. 295 - 309.e12
• Main Authors: Bosse, Kristopher R., Raman, Pichai, Zhu, Zhongyu, Lane, Maria, Martinez, Daniel, Heitzeneder, Sabine, Rathi, Komal S., Kendsersky, Nathan M., Randall, Michael, Donovan, Laura, Morrissy, Sorana, Sussman, Robyn T., Zhelev, Doncho V., Feng, Yang, Wang, Yanping, Hwang, Jennifer, Lopez, Gonzalo, Harenza, Jo Lynne, Wei, Jun S., Pawel, Bruce, Bhatti, Tricia, Santi, Mariarita, Ganguly, Arupa, Khan, Javed, Marra, Marco A., Taylor, Michael D., Dimitrov, Dimiter S., Mackall, Crystal L., Maris, John M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 11.09.2017
• Subjects: Animals; Antibodies, Neoplasm - metabolism; antibody-drug conjugate; Cell Death; Cell Line, Tumor; Cell Membrane - metabolism; Cell Proliferation; Child; Gene Expression Regulation, Neoplastic; Genome, Human; glypican; Glypicans - metabolism; Humans; Immunotherapy; medulloblastoma; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; MYCN; N-Myc Proto-Oncogene Protein - metabolism; neuroblastoma; Neuroblastoma - genetics; Neuroblastoma - immunology; Neuroblastoma - pathology; Neuroblastoma - therapy; Oncogene Proteins - metabolism; Risk Factors; RNA, Messenger - genetics; RNA, Messenger - metabolism; neuroblastoma; MYCN; antibody-drug conjugate; glypican; medulloblastoma; immunotherapy
• ISSN: 1535-6108; 1878-3686; 1878-3686
• DOI: 10.1016/j.ccell.2017.08.003

We developed an RNA-sequencing-based pipeline to discover differentially expressed cell-surface molecules in neuroblastoma that meet criteria for optimal immunotherapeutic target safety and efficacy. Here, we show that GPC2 is a strong candidate immunotherapeutic target in this childhood cancer. We demonstrate high GPC2 expression in neuroblastoma due to MYCN transcriptional activation and/or somatic gain of the GPC2 locus. We confirm GPC2 to be highly expressed on most neuroblastomas, but not detectable at appreciable levels in normal childhood tissues. In addition, we demonstrate that GPC2 is required for neuroblastoma proliferation. Finally, we develop a GPC2-directed antibody-drug conjugate that is potently cytotoxic to GPC2-expressing neuroblastoma cells. Collectively, these findings validate GPC2 as a non-mutated neuroblastoma oncoprotein and candidate immunotherapeutic target. [Display omitted] •Neuroblastomas differentially express high levels of GPC2 versus normal tissues•MYCN and gain of chromosome 7q mediate neuroblastoma GPC2 differential expression•GPC2 is integral in neuroblastoma cell proliferation•A GPC2-directed antibody-drug conjugate is cytotoxic to neuroblastoma cells Bosse et al. show that GPC2 is expressed at high levels on most neuroblastomas (NB) but not at appreciable levels in normal childhood tissues and that GPC2 is critical for NB maintenance. They develop a GPC2-directed antibody-drug conjugate that is cytotoxic to GPC2-expressing NB cells in vitro and in vivo.